PK/PD modelling to advance the preclinical development of a novel polymer prodrug in oncology - Archive ouverte HAL
Poster De Conférence Année : 2024

PK/PD modelling to advance the preclinical development of a novel polymer prodrug in oncology

Résumé

Background pharmacodynamics medthods : Taxanes such as Paclitaxel (PTX) are considered essential chemotherapeutics for the treatment of solid tumors. PTX formulations have been explored to increase efficacy, to reduce toxicities and have improved pharmacokinetics (PK). Treatment simulation - Results - Outline - PK/PD modeling: dose regimen optimization
Fichier principal
Vignette du fichier
poster_crs_2024_thermonano.pdf (1.1 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04719303 , version 1 (03-10-2024)

Identifiants

  • HAL Id : hal-04719303 , version 1

Citer

Anne Rodallec, Randy Lee, Sophie Marolleau, Sébastien Benzekry, Julien Nicolas. PK/PD modelling to advance the preclinical development of a novel polymer prodrug in oncology. CRS 2024 Annual Meeting and Expo : integrating Delivery Science across disciplines, Jul 2024, Bologna, Italy. ⟨hal-04719303⟩
23 Consultations
8 Téléchargements

Partager

More